Boston Scientific has obtained an approval in Europe for the latest addition to its pulsed field ablation portfolio, with the Farapoint focal catheter. The CE mark brings a new indication to the ...
MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use (IFU) ...
Boston Scientific has claimed a new approval from the FDA for its Farapulse pulsed field ablation system, expanding its use into patients with persistent atrial fibrillation lasting at least seven ...
Hosted on MSN
Boston Scientific’s global pulsed field ablation trial targets persistent atrial fibrillation growth
Boston Scientific (BSX) announced an update on their ongoing clinical study. Study Overview This global Boston Scientific trial, officially titled “A Global Randomized Trial Comparing Pulsed Field ...
Boston Scientific is proving itself to be a pivotal force in the pulsed-field ablation space. The Marlborough, MA-based company continues to be at the forefront of PFA with its technology The firm ...
Boston Scientific’s BSX Electrophysiology (“EP”) sales surged 63% in the third quarter of 2025, reflecting continued share gains in the overall EP market. FARAPULSE, the company’s Pulsed Field ...
The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ -- Boston Scientific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results